Lilly Gemzar
Executive Summary
Gemcitabine/cisplatin shows similar survival and less toxicity than a methotrexate/vinblastine/adriamycin/cisplatin regimen in a Phase III bladder cancer study reported at ASCO. Median survival was 13.8 months in the Gemzar arm and 14.8 months in the MVAC arm. The incidences of neutropenic sepsis, neutropenic fever and mucositis were lower in the Gemzar arm. Anemia and thrombocytopenia occurred more frequently in the Gemzar arm, however. Lilly submitted an sNDA for advanced bladder cancer in the third quarter of 1999. Gemzar is currently indicated for the treatment of pancreatic cancer and in combination with cisplatin for non-small cell lung cancer